Biograph mct truev

We performed a retrospective database analysis as part of an internal audit to identify patients evaluated between 2003 and 2018 with definite diagnosis of AE according to Graus and colleagues’ Position Paper [3 (link)]. We identified 6 patients in whom potential differential diagnoses were excluded by adequate tests, and who underwent autoantibodies analysis, MRI and electroencephalogram (EEG). Additionally, an early brain FDG-PET study was performed in all cases within the first week from the onset of symptoms. A whole-body –FDG-PET scan was added to the paraneoplastic workup of AE screening for malignancy in three patients (cases 1, 2 and 5). Patients fasted for at least 4 h before the study. Forty minutes after the injection of 336.7 ± 72.7 MBq of ¹⁸Fluorine-fluorodeoxyglucose, a 20-min PET/CT scan was acquired. All patients were scanned in a Siemens Biograph mCT TrueV. Acquisition and reconstruction were performed with the standard protocol for brain studies, as previously described [20 (link)]. Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants from whom identifiable information is included in this article.

The morning after the RE treatment, a ⁹⁰Y PET/CT scan centered on the liver region (two beds, 10 min/bed) was performed using a Biograph mCT-TrueV (Siemens Medical Solutions), which combines a 64-slice CT with a 21.8 cm field of view time-of-flight PET scanner comprised by lutetium-based crystals (LSO) detector blocks [22 (link)]. The reconstruction protocol used (one iteration, 21 subsets, a 6-mm Gaussian filter and a 200 × 200 matrix) was previously optimized by Martí-Climent et al. [11 (link)].
Final TgV in ⁹⁰Y PET/CT was defined using the multimodality reading software Syngo.via for MI (Siemens Healthneers) as previously described for ^99mTc-MAA-SPECT/CT.